Tumor necrosis in pediatric osteosarcoma: Impact of modern therapies

Journal of Pediatric Oncology Nursing

Volumn 23, Issue 4, 2006, Pages 176-181

  Hendershot, Eleanor ^a,b,c   Pappo, Alberto ^a,c,d   Malkin, David ^a,c   Sung, Lillian ^a,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Solid Tumor Program   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Solid Tumor Section   (United States)

Author keywords

Chemotherapy; Osteosarcoma; Prognostic factors; Survival; Tumor necrosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ARTICLE; BONE TUMOR; CANCER STAGING; CHILD; HUMAN; METHODOLOGY; MORTALITY; NECROSIS; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OSTEOTOMY; PATHOLOGY; PREDICTION AND FORECASTING; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CISPLATIN; DOXORUBICIN; HUMANS; MAGNETIC RESONANCE IMAGING; METHOTREXATE; NECROSIS; NEOPLASM STAGING; OSTEOSARCOMA; OSTEOTOMY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745112168     PISSN: 10434542     EISSN: 15328457     Source Type: Journal    
DOI: 10.1177/1043454206289786     Document Type: Article

References (17)

1. Bacci, G., Ferrari, S., Longhi, A., Forni, C., Zavatta, M., Versare, M., et al. (2002). High-grade osteosarcoma of the extremity: Differences between localized and metastatic tumors at presentation. Journal of Pediatric Hematology Oncology, 24, 27-30.
2. Barnett, A. G., van der Pols, J., & Dobson, A. J. (2005). Regression to the mean: What it is and how to deal with it. International Journal of Epidemiology, 34, 215-220.
3. Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Fledge, S., Helmke, K., et al. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 20, 776-790.
4. Davis, A. M., Bell, R. S., & Goodwin, P. J. (1994). Prognostic factors in osteosarcoma: A critical review. Journal of Clinical Oncology, 12, 423-431.
5. Eilber, F. C., Rosen, G., Eckardt, J., Forscher, C., Nelson, S. D., Selch, M., et al. (2001). Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. Journal of Clinical Oncology, 19, 3203-3209.
6. Goorin, A. M., Harris, M. B., Bernstein, M., Ferguson, W., Devidas, M., Siegal, G. P., et al. (2002). Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. Journal of Clinical Oncology, 20(2) 426-433.
7. Hartford, C. M., Wodowski, K. S., Rao, B. N., Khoury, J. D., Neel, M. D., & Daw, N. C. (2006). Osteosarcoma among children aged 5 years or younger: The St. Jude children's research hospital experience. Journal of Pediatric Hematology Oncology, 28, 43-47.
8. Jurgens, H., Winkler, K., & Gobel, U. (1997). Bone tumours. In C. R. Pinkerton & P. N. Plowman (Eds.), Paediatric oncology (2nd ed., pp. 417-439). London: Chapman & Hall.
9. Kager, L., Zoubek, A., Potschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., et al. (2003). Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 21, 2011-2018.
10. Link, M. P., Gebhardt, M. C., & Meyers, P. A. (2002). Osteosarcoma. In P. A. Pizzo & D. G. Poplack (Eds.), Principles and practice of pediatric oncology (4th ed., pp. 1051-1090). Philadelphia: Lippincott Williams & Wilkins.
11. Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 9, 422-441.
12. Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E., Betcher, D., Bernstein, M. L., et al. (2005). Osteosarcoma: A randomized, prospective trial of the addition of the ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology, 23, 2004-2011.
13. Morton, V., & Torgerson, D. J. (2003). Effect of regression to the mean on decision making in health care. British Medical Journal, 326, 1083-1084.
14. Pinkerton, C. R. (1999). Osteogenic sarcoma. In C. R. Pinkerton, A. J. Michalski, & P. A. Veys (Eds.), Clinical challenges in paediatric oncology (pp. 127-134). Oxford, UK: ISIS Medical Medial.
15. Ragland, B. D., Bell, W. C., Lopez, R. R., & Siegal, G. P. (2002). Cytogenetic and molecular biology of osteosarcoma. Laboratory Investigation, 82, 365-377.
16. Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979). Primary osteogenic sarcoma. The rational for pre-operative chemotherapy and delayed surgery. Cancer, 43, 2163-2177.
17. Zalupski, M. M., Rankin, C., Ryan, J. R., Lucas, D. R., Muler, J., Lanier, K. S., et al. (2004). Adjuvant therapy of osteosarcoma - A phase II trial. Cancer, 100, 818-825.